63618-60-0

Upstream product

• 67-56-1 methanol 
• 31270-80-1 4-chlorofuro[3,2-c]pyridine 
• 57420-06-1 furo<3,2-c>pyridine N-oxide 
• 124-41-4 sodium methylate 

Downstream Products

• 86518-09-4 formyl-2 methoxy-4 furo<3,2-c>pyridine 
• 86518-17-4 formyl-2 dihydro-4,5 oxo-4 furo<3,2-c>pyridine 
• 1301610-75-2 4-methoxy-3-phenylfuro[3,2-c]pyridine 

Relevant academic research and scientific papers

Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof

The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,

BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides a Degronimer that has an E3 Ubiquitin Ligase targeting moiety (Degron) that can be linked to a Targeting Ligand for a bromodomain protein selected for in vivo degradation to achieve a therapeutic effect, and methods of use and compositions thereof as well as methods for their preparation.

SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ("Degrons"), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

AKT / PKB INHIBITORS

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Furopyridines. XXIII [1]. Synthesis and Reactions of Chloropyridine Derivatives of Furo[2,3-b]-, -[2,3-c]- and -[3,2-c]pyridine

Chlorination of the N-oxides of furo[2,3-b]- 1a, -[2,3-c]- 1b and -[3,2-c]pyridine 1c with phosphorus oxychloride afforded compounds substituted normally at the α- or γ-position to the ring nitrogen, 2a, 2′a, 2b, 2c, 2′c and 2″c, and in addition, in the case of 1b, compounds substituted on the furan ring, 2′b and 2″b. The structures of these compounds were confirmed from their ir, nmr and mass spectra. The major chlorinated products 2a, 2b and 2c were converted to methoxy- 5a, 5b and 5c, N-pyrrolidyl- 7a, 7b and 7c, and phenylthiofuropyridines 8a, 8b, and 8c.

LITHIATION DE FURO- ET PYRROLOPYRIDINES SUBSTITUEES SUR LEUR POSITION 4

Lithiation of the title compounds using t-butyl lithium occurs at c-2 of the five-membered ring.